We do not prefer this scenario because GABAB-R agonists have been shown to (1) inhibit murine dendritic cell (DC) activation and immune cell chemotaxis34,35, (2) inhibit DC proinflammatory functions34, (3) alleviate collagen-induced arthritis and contact dermatitis in mouse models34,35, (4) delay T1D onset in NOD mice36, and (5) attenuate TLR4-induced inflammatory signaling in human PBMC37. Here, TLR4 is linked to arthritic joint disease.